West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
West Pharmaceutical Services is rated a buy, supported by strong Q3 results, raised guidance, and a resilient long-term growth thesis. WST's focus on high-value proprietary elastomer components and secular industry drivers, like GLP-1 demand, underpins robust margin and revenue growth. Risks include questionable capital allocation, recent insider selling during buybacks, and potential disruption from oral drug alternatives.
West Pharmaceutical Services, Inc. ( WST ) Stephens Annual Investment Conference 2025 November 20, 2025 12:00 PM EST Company Participants Robert McMahon - Senior VP & CFO Shane Campbell - SVP & Chief Proprietary Segment Officer John Sweeney - Head of Investor Relations Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division Welcome to day 3 of Stephens 2025 Investment Conference here at Nashville. I'm Mac Etoch, the Life Science Tools and Pharma Services Analyst.
| - Industry | - Sector | Eric M. Green CEO | XHAN Exchange | US9553061055 ISIN |
| US Country | 10,600 Employees | 12 Nov 2025 Last Dividend | 27 Sep 2013 Last Split | 13 Jan 1978 IPO Date |
West Pharmaceutical Services, Inc. is a leading global provider in the design, manufacturing, and sale of containment and delivery systems for injectable drugs and healthcare products. With a presence across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, the company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. Founded in 1923 and headquartered in Exton, Pennsylvania, West Pharmaceutical Services, Inc. is dedicated to serving biologic, generic, and pharmaceutical drug companies, as well as pharmaceutical, diagnostic, and medical device companies through a comprehensive sales force, distribution network, contract sales agents, and regional distributors.